Stemline Therapeutics Announces Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming AS...
November 06 2019 - 9:15AM
Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage
biopharmaceutical company focused on the development and
commercialization of novel oncology therapeutics, announced today
that ELZONRIS (tagraxofusp; SL-401), a novel targeted therapeutic
directed to CD123, will be featured in three presentations,
including an oral presentation of ELZONRIS clinical data in
myelofibrosis, at the 2019 American Society of Hematology (ASH)
Annual Meeting and Exposition, to be held December 7-10, 2019 in
Orlando, FL.
Details on the ASH presentations are as follows:
Myelofibrosis – Clinical (monotherapy); oral
presentation |
Title: |
Results from a Phase 1/2 Clinical Trial of Tagraxofusp
(SL-401) in Patients with Intermediate, or High Risk,
Relapsed/Refractory Myelofibrosis |
Presenter: |
Naveen Pemmaraju, MD; MD Anderson Cancer
Center |
Abstract: |
558 |
Session: |
634. Myeloproliferative Syndromes: Clinical: Emerging and
Novel Targeted Therapies |
Date/Time: |
Monday, December 9, 2019 8:15 AM ET |
Location: |
Orange County Convention Center, W304EFGH |
|
Multiple Myeloma – Clinical (combination therapy); poster
presentation |
Title: |
Results from Phase 1/2 Trial of Tagraxofusp in Combination
with Pomalidomide and Dexamethasone in Relapsed or Refractory
Multiple Myeloma |
Presenter: |
Paul G. Richardson, M.D.; Dana-Farber Cancer
Institute |
Abstract: |
3145 |
Session: |
653. Myeloma: Therapy, excluding Transplantation: Poster
II |
Date/Time: |
Sunday, December 8, 2019 6:00 PM–8:00 PM ET |
Location: |
Orange County Convention Center, Hall B |
|
Myeloproliferative Neoplasms – Preclinical (combination
therapy); poster presentation |
Title: |
Evaluation of Tagraxofusp (SL-401) Alone and in Combination
with Ruxolitinib for the Treatment of Myeloproliferative
Neoplasms |
Presenter: |
Aishwarya Krishnan, MD; Memorial Sloan Kettering Cancer
Center |
Abstract: |
2967 |
Session: |
635. Myeloproliferative Syndromes: Basic Science: Poster
II |
Date/Time: |
Sunday, December 8, 2019 6:00 PM–8:00 PM ET |
Location: |
Orange County Convention Center, Hall B |
|
|
Ivan Bergstein, M.D., CEO of Stemline Therapeutics, commented,
“We are honored that ASH has selected ELZONRIS data as the subject
of three presentations, including an oral presentation of clinical
trial data in myelofibrosis (MF). Moreover, given the very
encouraging trial results to date that we have witnessed, we are
expanding the current cohort to enable additional patient
enrollment. Two other presentations, including ELZONRIS clinical
combination data in patients with multiple myeloma, and ELZONRIS
preclinical combination data in myeloproliferative neoplasms,
highlight ELZONRIS’ potential utility across indications. In
addition, as we now transition our chronic myelomonocytic leukemia
(CMML) program to registration-directed, we remain on track to
begin enrollment of the Stage 3a cohort in patients with CMML in
the coming months, with the goal of reporting data from this
cohort, in both the relapsed/refractory and first-line settings, by
2H20.”
About ELZONRIS®
ELZONRIS® (tagraxofusp-erzs), a CD123-directed cytotoxin, is
approved by the U.S. Food and Drug Administration (FDA) and
commercially available in the U.S. for the treatment of adult and
pediatric patients, two years or older, with blastic plasmacytoid
dendritic cell neoplasm (BPDCN). For full prescribing information
in the U.S., visit www.ELZONRIS.com. In Europe, a marketing
authorization application (MAA) is under review by the European
Medicines Agency (EMA). ELZONRIS is also being evaluated in
additional clinical trials in other indications including chronic
myelomonocytic leukemia (CMML), myelofibrosis (MF), and acute
myeloid leukemia (AML).
About BPDCN BPDCN is an aggressive hematologic
malignancy with historically poor outcomes and an area of unmet
medical need. BPDCN typically presents in the bone marrow and/or
skin and may also involve lymph nodes and viscera. The BPDCN cell
of origin is the plasmacytoid dendritic cell (pDC) precursor. The
diagnosis of BPDCN is based on the immunophenotypic diagnostic
triad of CD123, CD4, and CD56, as well as other markers. For more
information, please visit the BPDCN disease awareness website at
www.bpdcninfo.com.
About CD123CD123 is a cell surface target
expressed on a wide range of myeloid tumors including blastic
plasmacytoid dendritic cell neoplasm (BPDCN), certain
myeloproliferative neoplasms (MPNs) including chronic
myelomonocytic leukemia (CMML) and myelofibrosis (MF), acute
myeloid leukemia (AML) (and potentially enriched in certain AML
subsets), myelodysplastic syndrome (MDS), and chronic myeloid
leukemia (CML). CD123 has also been reported on certain lymphoid
malignancies including multiple myeloma (MM), acute lymphoid
leukemia (ALL), hairy cell leukemia (HCL), Hodgkin’s lymphoma (HL),
and certain Non-Hodgkin’s lymphomas (NHL). In addition, CD123 has
been detected on some solid tumors as well as autoimmune disorders
including cutaneous lupus and scleroderma.
About Stemline Therapeutics Stemline
Therapeutics, Inc. is a commercial-stage biopharmaceutical company
focused on the development and commercialization of novel oncology
therapeutics. ELZONRIS® (tagraxofusp), a targeted therapy
directed to CD123, is FDA-approved and commercially available in
the U.S. for the treatment of adult and pediatric patients, two
years and older, with blastic plasmacytoid dendritic cell neoplasm
(BPDCN). In Europe, a marketing authorization application (MAA) is
under review by the European Medicines Agency (EMA). ELZONRIS is
also being evaluated in clinical trials in additional indications
including chronic myelomonocytic leukemia (CMML), myelofibrosis
(MF) and acute myeloid leukemia (AML). Additional pipeline
candidates include: felezonexor (SL-801) (XPO1 inhibitor; Phase 1
in advanced solid tumor patients ongoing), SL-1001 (novel RET
kinase inhibitor, IND-enabling studies ongoing), SL-701
(immunotherapeutic; Phase 2 in glioblastoma patients completed),
and SL-901 (novel kinase inhibitor; prior abbreviated European
Phase 1, IND-enabling studies ongoing). For more information,
please visit the company’s website at www.stemline.com.
Forward-Looking StatementsSome of the
statements included in this press release may be forward-looking
statements that involve a number of risks and uncertainties. For
those statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. The factors that could cause our
actual results to differ materially include: the success of our
U.S. launch and commercialization; the success of our MAA
submission to the EMA and potential launch in Europe; the success
and timing of our clinical trials and preclinical studies for our
product and product candidates, including ELZONRIS in additional
indications and our other pipeline candidates, including site
initiation, institutional review board approval, scientific review
committee approval, patient accrual, safety, tolerability and
efficacy data observed, and input from regulatory authorities
including the risk that the FDA, EMA, or other ex-U.S. national
drug authority ultimately does not agree with our data, find our
data supportive of approval, or approve any of our product
candidates; the possibility that results of clinical trials are not
predictive of safety and efficacy results of our product candidates
in broader patient populations or of our products if approved; our
plans to develop and commercialize our product candidates,
including, but not limited to delays in arranging satisfactory
manufacturing capabilities and establishing commercial
infrastructure for ELZONRIS; product efficacy or safety concerns
resulting in product recalls or regulatory action; the risk that
estimates regarding the number of patients with the diseases that
our product and product candidates may treat are inaccurate;
inadequate market penetration of our products; our products not
gaining acceptance among patients (and providers or third party
payors) for certain indications (due to cost or otherwise); the
risk that third party payors (including governmental agencies) will
not reimburse for the use of ELZONRIS at acceptable rates or at
all; the company’s ability to produce, maintain or increase sales
of ELZONRIS; the company’s ability to develop and/or commercialize
ELZONRIS; the adequacy of our pharmacovigilance and drug safety
reporting processes; our available cash and investments; our
ability to obtain and maintain intellectual property protection for
our product and product candidates; delays, interruptions, or
failures in the manufacture and supply of our product and product
candidates; the performance of third-party businesses, including,
but not limited to, manufacturers, clinical research organizations,
clinical trial sponsors and clinical trial investigators; and other
risk factors identified from time to time in our reports filed with
the SEC. Any forward-looking statements set forth in this press
release speak only as of the date of this press release. We do not
intend to update any of these forward-looking statements to reflect
events or circumstances that occur after the date hereof.
Contact: Investor RelationsStemline
Therapeutics, Inc.750 Lexington AvenueEleventh FloorNew York, NY
10022Tel: 646-502-2307Email: investorrelations@stemline.com
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Aug 2024 to Sep 2024
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Sep 2023 to Sep 2024